Drs. Keto and Freedland from Duke University studied obesity in men with treated prostate cancer. Men who are on androgen deprivation therapy (ADT) for recurrent prostate cancer after prostatectomy do worse on the therapy when obese compared to men who are not obese. They used the SEARCH database compiled over 21 years from 1998 to 2009 for the source of analytic data. 287 men were identified who were on ADT early. Normal weight was considered a BMI of less than 25, overweight was BMI of 25-29.9, and obese was BMI greater than 30. After comparing the data, weight independently showed a difference in response to therapy, with a three-fold higher risk for progression to ADT-resistant disease if overweight or obese. <\/p>\n
Furthermore, the risk of metastases was three times higher if overweight and five times higher if obese.<\/p>\n
There are multiple possible reasons for this, but the result is the same regardless of the reason. So please drop the weight. Not only will you feel better… you will also be healthier. <\/p>\n","protected":false},"excerpt":{"rendered":"